Female Reproductive Factors
On sale on the US market (according to the DSLD)
Michael's Naturopathic Programs, food supplement from the US market
Female Reproductive Factors (Michael's Naturopathic Programs), a food supplement au code-barres 755929012732, is described by its US market label. If sold in France, it would be subject to 4 points of French or European regulation, detailed below. Doses of folates, niacine, vitamine A are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine C: up to 500 mg a day according to the label (at most 1 serving a day), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Vitamine E: up to 150 mg a day according to the label (at most 1 serving a day), above the maximum dose of 30 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Conditions légales
Linum usitatissimum L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Turnera diffusa Willd. ex Schult.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Michael's Naturopathic Programs
- Barcode
- 755929012732
- Form
- Tablet
- One serving
- 3 tablets
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Microcrystalline Cellulose, Dicalcium Phosphate, Stearic Acid, modified Cellulose Gum, Vegetable Magnesium Stearate, Silicon Dioxide, Hydroxypropyl Methylcellulose
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin A | Vitamin | 1,500 µg |
| Vitamin C | Vitamin | 500 mg |
| Vitamin E | Vitamin | 150 mg |
| Thiamine | Vitamin | 50 mg |
| Niacin | Vitamin | 50 mg |
| Folate | Vitamin | 150 µg DFE (dietary folate equivalent) |
| Pantothenic Acid | Vitamin | 50 mg |
| Calcium | Mineral | 60 mg |
| OptiZinc | Mineral | 75 mg |
| Proprietary Blend | Blend | 987 mg |
| Flax seed extract (Linum usitatissimum) | Plant | not stated |
| Asian Ginseng (Panax ginseng) | Plant | not stated |
| Damiana (Turnera diffusa) | Plant | not stated |
| Licorice | Plant | not stated |
| Gotu Kola (Centella asiatica) | Plant | not stated |
| Red Raspberry (Rubus idaeus) | Plant | not stated |
| Wild Yam | Plant | not stated |
| Cayenne (Capsicum annuum) | Plant | not stated |
| Clove (Syzygium aromaticum) | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Male Reproductive Factors
Entered into DSLD on 22 September 2022. On sale on the US market (according to the DSLD).- Active ingredient added : Fenugreek (quantity not stated)
- Active ingredient added : Inositol (quantity not stated)
- Active ingredient added : L-Arginine (quantity not stated)
- Active ingredient added : L-Cysteine Hydrochloride (quantity not stated)
- Active ingredient added : L-Glutamine (quantity not stated)
- Active ingredient added : Magnesium (50 mg)
- Active ingredient added : Manganese (11 mg)
- Active ingredient added : Saw Palmetto (quantity not stated)
- Active ingredient added : Selenium (50 mcg)
- Active ingredient added : Vitamin B12 (250 mcg)
- Active ingredient removed : Cayenne (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Gotu Kola (quantity not stated)
- Active ingredient removed : Licorice (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Active ingredient removed : Red Raspberry (quantity not stated)
- Active ingredient removed : Thiamine (50 mg)
- Active ingredient removed : Wild Yam (quantity not stated)
- Different quantity per serving : Calcium: 96 mg in this version; 60 mg on the displayed label
- Different quantity per serving : OptiZinc: 30 mg in this version; 75 mg on the displayed label
- Different quantity per serving : Pantothenic Acid: 100 mg in this version; 50 mg on the displayed label
- Different quantity per serving : Proprietary Blend: 725 mg in this version; 987 mg on the displayed label
- Different quantity per serving : Vitamin A: 750 mcg in this version; 1,500 mcg on the displayed label
- Different quantity per serving : Vitamin C: 300 mg in this version; 500 mg on the displayed label
- Different quantity per serving : Vitamin E: 67 mg in this version; 150 mg on the displayed label
Official label: Female Reproductive Factors
Entered into DSLD on 22 May 2021. On sale on the US market (according to the DSLD).- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Same quantity, different name: Olive leaf extract in this version; OptiZinc on the displayed label (75 mg)
- Different quantity per serving : Folate: 138 mcg DFE in this version; 150 mcg DFE on the displayed label
Official label: Male Reproductive Factors
Entered into DSLD on 22 April 2021. On sale on the US market (according to the DSLD).- Active ingredient added : Fenugreek (quantity not stated)
- Active ingredient added : Inositol (quantity not stated)
- Active ingredient added : L-Arginine (quantity not stated)
- Active ingredient added : L-Cysteine Hydrochloride (quantity not stated)
- Active ingredient added : L-Glutamine (quantity not stated)
- Active ingredient added : Magnesium (50 mg)
- Active ingredient added : Manganese (11 mg)
- Active ingredient added : Olive leaf extract (30 mg)
- Active ingredient added : Saw Palmetto (quantity not stated)
- Active ingredient added : Selenium (50 mcg)
- Active ingredient added : Vitamin B12 (250 mcg)
- Active ingredient removed : Cayenne (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Gotu Kola (quantity not stated)
- Active ingredient removed : Licorice (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Active ingredient removed : OptiZinc (75 mg)
- Active ingredient removed : Red Raspberry (quantity not stated)
- Active ingredient removed : Thiamine (50 mg)
- Active ingredient removed : Wild Yam (quantity not stated)
- Different quantity per serving : Calcium: 96 mg in this version; 60 mg on the displayed label
- Different quantity per serving : Folate: 138 mcg DFE in this version; 150 mcg DFE on the displayed label
- Different quantity per serving : Pantothenic Acid: 100 mg in this version; 50 mg on the displayed label
- Different quantity per serving : Proprietary Blend: 725 mg in this version; 987 mg on the displayed label
- Different quantity per serving : Vitamin A: 750 mcg in this version; 1,500 mcg on the displayed label
- Different quantity per serving : Vitamin C: 300 mg in this version; 500 mg on the displayed label
- Different quantity per serving : Vitamin E: 67 mg in this version; 150 mg on the displayed label
Official label: Male Reproductive Factors
Entered into DSLD on 24 June 2020. Withdrawn from the US market on 12 March 2021 (according to the DSLD).- Active ingredient added : (6S)-5-Methyltetrahydrofolic Acid, Glucosamine Salt (300 mcg)
- Active ingredient added : Fenugreek (quantity not stated)
- Active ingredient added : Inositol (quantity not stated)
- Active ingredient added : L-Arginine (quantity not stated)
- Active ingredient added : L-Cysteine Hydrochloride (quantity not stated)
- Active ingredient added : L-Glutamine (quantity not stated)
- Active ingredient added : Magnesium (50 mg)
- Active ingredient added : Manganese (11 mg)
- Active ingredient added : Saw Palmetto (quantity not stated)
- Active ingredient added : Selenium (50 mcg)
- Active ingredient added : Vitamin B12 (250 mcg)
- Active ingredient added : Zinc (30 mg)
- Active ingredient removed : Cayenne (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Gotu Kola (quantity not stated)
- Active ingredient removed : Licorice (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Active ingredient removed : OptiZinc (75 mg)
- Active ingredient removed : Red Raspberry (quantity not stated)
- Active ingredient removed : Thiamine (50 mg)
- Active ingredient removed : Wild Yam (quantity not stated)
- Different quantity per serving : Calcium: 96 mg in this version; 60 mg on the displayed label
- Different quantity per serving : Pantothenic Acid: 100 mg in this version; 50 mg on the displayed label
- Different quantity per serving : Proprietary Blend: 725 mg in this version; 987 mg on the displayed label
- Different quantity per serving : Vitamin A: 750 mcg in this version; 1,500 mcg on the displayed label
- Different quantity per serving : Vitamin C: 300 mg in this version; 500 mg on the displayed label
- Different quantity per serving : Vitamin E: 67 mg in this version; 150 mg on the displayed label
Official label: Female Reproductive Factors
Entered into DSLD on 24 June 2020. Withdrawn from the US market on 23 December 2021 (according to the DSLD).- Active ingredient added : (6S)-5-Methyltetrahydrofolic Acid, Glucosamine Salt (300 mcg)
- Active ingredient added : Flax (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Same quantity, different name: Zinc in this version; OptiZinc on the displayed label (75 mg)
Official label: Female Reproductive Factors
Entered into DSLD on 24 June 2016. On sale on the US market (according to the DSLD).- Active ingredient added : Oriental Ginseng (quantity not stated)
- Active ingredient removed : Asian Ginseng (quantity not stated)
- Active ingredient removed : Calcium (60 mg)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Same quantity, different name: Olive leaf extract in this version; OptiZinc on the displayed label (75 mg)
- Different unit, without conversion : Folate: 150 mcg in this version; 150 mcg DFE on the displayed label
- Different unit, without conversion : Vitamin A: 5,000 IU in this version; 1,500 mcg on the displayed label
- Different unit, without conversion : Vitamin E: 225 IU in this version; 150 mg on the displayed label
Official label: Female Reproductive Factors
Entered into DSLD on 22 May 2015. Withdrawn from the US market on 13 February 2020 (according to the DSLD).- Active ingredient added : Flax (quantity not stated)
- Active ingredient added : Oriental Ginseng (quantity not stated)
- Active ingredient removed : Asian Ginseng (quantity not stated)
- Active ingredient removed : Calcium (60 mg)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Same quantity, different name: Olive leaf extract in this version; OptiZinc on the displayed label (75 mg)
- Different unit, without conversion : Folate: 150 mcg in this version; 150 mcg DFE on the displayed label
- Different unit, without conversion : Vitamin A: 5,000 IU in this version; 1,500 mcg on the displayed label
- Different unit, without conversion : Vitamin E: 225 IU in this version; 150 mg on the displayed label
Official label: Male Reproductive Factors
Entered into DSLD on 22 May 2015. Withdrawn from the US market on 13 February 2020 (according to the DSLD).- Active ingredient added : Arginine (quantity not stated)
- Active ingredient added : Fenugreek (quantity not stated)
- Active ingredient added : Glutamine (quantity not stated)
- Active ingredient added : Inositol (quantity not stated)
- Active ingredient added : L-Cysteine Hydrochloride (quantity not stated)
- Active ingredient added : Magnesium (50 mg)
- Active ingredient added : Manganese (11 mg)
- Active ingredient added : Methionine (quantity not stated)
- Active ingredient added : Olive leaf extract (30 mg)
- Active ingredient added : Oriental Ginseng (quantity not stated)
- Active ingredient added : Saw Palmetto (quantity not stated)
- Active ingredient added : Selenium (50 mcg)
- Active ingredient added : Vitamin B12 (250 mcg)
- Active ingredient removed : Asian Ginseng (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Flax seed extract (quantity not stated)
- Active ingredient removed : Gotu Kola (quantity not stated)
- Active ingredient removed : Licorice (quantity not stated)
- Active ingredient removed : Niacin (50 mg)
- Active ingredient removed : OptiZinc (75 mg)
- Active ingredient removed : Red Raspberry (quantity not stated)
- Active ingredient removed : Thiamine (50 mg)
- Active ingredient removed : Wild Yam (quantity not stated)
- Different quantity per serving : Calcium: 315 mg in this version; 60 mg on the displayed label
- Different quantity per serving : Pantothenic Acid: 100 mg in this version; 50 mg on the displayed label
- Different quantity per serving : Proprietary Blend: 775 mg in this version; 987 mg on the displayed label
- Different quantity per serving : Vitamin C: 300 mg in this version; 500 mg on the displayed label
- Different unit, without conversion : Folate: 150 mcg in this version; 150 mcg DFE on the displayed label
- Different unit, without conversion : Vitamin A: 2,500 IU in this version; 1,500 mcg on the displayed label
- Different unit, without conversion : Vitamin E: 100 IU in this version; 150 mg on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Flax seed extract
Read the warning, when it applies and the studies cited
FLAXSEED - LINUM USITATISSIMUM
Route of administration: Oral
Cautions and warnings
Applies to products providing 5 g or more of flaxseed per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).
Sources cited by Health Canada (1)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Condition of application: Laxative; Promotion of bowel movement; Constipation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).
Sources cited by Health Canada (2)
- Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
- Repchinsky 2002: Canadian Pharmacists Association. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.
Contraindications
Applies to products providing 5 g or more of flaxseed per day.
Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Gardner Z. and McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. American Herbal Products Association. Boca Raton (FL): CRC Press; 2013.
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- León F, Rodríguez M, Cuevas M. 2003. Anaphylaxis to Linum. Allergologia et immunopathologia 31(1):47-49.
- Asian Ginseng
Read the warning, when it applies and the studies cited
PANAX GINSENG
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Clinical trial
- Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
- Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Case report
- Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
- Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Case report
- Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Randomised trial
- Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Case report
- Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Case report
Contraindications
Condition of application: Traditional Chinese Medicine.
Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).
Sources cited by Health Canada (1)
- Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
Known adverse reactions
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).
Sources cited by Health Canada (8)
- Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Systematic review
- de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
- Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Randomised trial
- Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Randomised trial
- Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
- Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Cayenne
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Michael's Naturopathic Programs
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Female Reproductive Factors (Michael's Naturopathic Programs): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/755929012732-female-reproductive-factors-michael-s-naturopathic-programs, updated 22 September 2022.